RYTM 59.03 (-0.56%)
US76243J1051BiotechnologyBiotechnology

Rhythm Pharmaceuticals (RYTM) Financial Metrics

This table shows a selected set of financial data points of Rhythm Pharmaceuticals (RYTM). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -3.2 0 -14.36 2.65B -0.52 77.43M -136.2M -168.46M -184.68M 60.08M
2022 -3.48 0 -8.38 1.52B -0.51 23.64M -177.71M -174.25M -181.12M 127.68M
2021 -1.4 0 -7.11 495.01M -0.27 3.15M -151.44M -68.45M -69.61M 59.25M
2020 -3.04 0 -9.79 1.31B -0.54 0 -122.19M -133.31M -134M 100.85M
2019 -3.86 0 -5.94 836.26M -0.49 0 -126.14M -146M -140.73M 62.29M
2018 -2.39 0 -11.25 833.39M -0.36 0 -62.78M -73.62M -74.06M 49.54M
2017 -2.54 0 -11.44 385.57M -0.41 0 -29.59M -33.49M -33.71M 34.24M
2016 -1.78 0 0 0 -1.04 0 -24.28M -25.73M -25.87M 6.54M
2015 -0.66 0 0 0 -0.59 0 -6.99M -11.07M -11.07M 34.87M
2014 -0.65 0 0 0 -0.71 0 0 0 -6.49M 152K
2013 -0.43 0 0 0 -1.16 0 -19.16M -21.41M -21.43M 7.36M
2012 -0.36 0 0 0 0 0 -17.83M -18.11M -18.13M 11.77M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.